FY2025 · ended Dec 31, 2025 · Revenue $12.00B, +8.9% YoY · Filed Feb 13, 2026
Vertex Pharmaceuticals Inc / Ma (VRTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $12.0 billion and net income of $4.0 billion. Free cash flow was $3.2 billion. As of Sep 30, 2026 it held $9.8 billion in cash and investments and $6.5 billion in total debt.
Revenue (TTM)
$12.95B
+10.5% vs year-ago TTM
Net income (TTM)
$3.98B
+8.2% vs year-ago TTM
Operating cash flow (TTM)
$3.69B
-0.6% vs year-ago TTM
Free cash flow (TTM)
$3.20B
-4.0% vs year-ago TTM
EPS (TTM)
$15.55
+9.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
254.03M
-1.1% vs prior year
Net cash
$3.34B
as of Sep 30, 2026
Operating margin
33.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B |
| Operating income | $4.2B | -$232.9M | $3.8B | $4.3B | $2.8B |
| Net income | $4.0B | -$535.6M | $3.6B | $3.3B | $2.3B |
| Diluted EPS | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 |
| Operating cash flow | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B |
| Free cash flow | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B |
| Stockholders' equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B |
| Cash and investments | $12.3B | $11.2B | $13.7B | $10.8B | $7.5B |
| Total debt | $2.0B | $1.7B | $808.4M | $899.7M | $967.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 1, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
All 1001 Vertex Pharmaceuticals Inc / Ma SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.